 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Course Fundamentals

Distinguishing Degradation Products from Process Impurities

Course Overview

Measurable Learning Objectives

ICH Q3B(R2) Core Concepts and Case Studies

Slide 1: Opening Hook (45 sec)

Slide 2: Concept Simplified (60 sec)

Slide 3: Case Study with Characters (90 sec)

Slide 4: Practical Application (60 sec)

10 Key Concepts

Compliance & Best Practices

10-Point Audit / Inspection Checklist

Slide 5: Knowledge Check + Takeaways (45 sec)

Quiz

Course Evaluation

Part B — Reflection (On-Screen)

Part C — Top 5 Takeaways

Are you struggling to confidently distinguish between degradation products and process impurities in your drug product specifications. Misclassifying these critical components can lead to regulatory delays, compliance warnings, and compromised patient safety.

Are you struggling to confidently distinguish between degradation products and process impurities in your drug product specifications? Misclassifying these critical components can lead to regulatory delays, compliance warnings, and compromised patient safety. Welcome to 'Distinguishing Degradation Products from Process Impurities per ICH Q3B(R2),' a comprehensive online course designed specifically for pharmaceutical analysts, quality assurance professionals, and regulatory affairs specialists.

This course dives deep into the fundamental concepts, purpose, and scope of the ICH Q3B(R2) guidelines. You will learn how to accurately identify the boundary between ICH Q3A (drug substance impurities) and ICH Q3B (drug product degradation products). Through engaging modules, we will explore common industry pitfalls—such as the risks of simply copy-pasting a drug substance impurity profile onto a drug product specification—and provide you with the tools to avoid them.

Featuring realistic case studies, practical workflows, and a robust 10-point audit and inspection checklist, this training bridges the gap between theoretical guidelines and day-to-day laboratory application. You will master the correct workflow for classifying unknown peaks using stability trending, forced degradation evidence, and mass balance. By the end of this course, you will possess the evidence-based decision-making skills required to defend the impurity sections of your regulatory dossiers, ensuring your laboratory specifications meet strict inspection readiness standards. Enroll today to safeguard your product quality and elevate your regulatory compliance expertise!

114. Distinguishing Degradation Products from Process Impurities per ICH Q3B(R2)

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>Regulatory compliance in pharmaceutical manufacturing demands a precise understanding of impurity profiling and specification development. A critical challenge frequently encountered by Quality Control (QC) analysts, Quality Assurance (QA) reviewers, and Regulatory CMC staff is accurately distinguishing between degradation products and process impurities. Misclassifications—such as erroneously duplicating a drug substance impurity profile onto a drug product specification or dismissing a rising chromatographic peak as merely process-related—can precipitate severe regulatory and quality risks. This curriculum provides a rigorous examination of the ICH Q3B(R2) guidelines, clearly delineating the regulatory boundary between drug substance impurities, which are governed by ICH Q3A, and drug product degradation products.</p>

<p>To bridge specific knowledge gaps in impurity profiling, this course integrates theoretical frameworks with practical, scenario-based applications. Participants will analyze realistic stability case studies to differentiate between compliant, evidence-based classifications and non-compliant, assumption-based decisions. The instructional modules detail the correct analytical workflows for classifying unknown peaks, leveraging stability trending, forced degradation evidence, and mass balance. Additionally, the program provides actionable compliance tools, including a comprehensive 10-point audit checklist to evaluate laboratory specifications and stability-indicating methods. By mastering these foundational concepts, analytical, manufacturing, and regulatory professionals will achieve the competencies necessary to confidently defend dossier impurity sections, thereby safeguarding product quality, ensuring patient safety, and maintaining rigorous inspection readiness.</p>
        </div>
    </div>
</div>
